MGF (Mechano-Growth Factor): IGF-1 splice variant research overview

Mechano-Growth Factor (MGF) is a splice variant of insulin-like growth factor 1 (IGF-1) generated in response to mechanical stress and muscle damage. Characterized by Geoffrey Goldspink and colleagues at University College London beginning in the mid-1990s, MGF — encoded by the IGF-1Ec exon in humans (IGF-1Eb in rodents) — is distinguished from the liver-derived, circulating IGF-1Ea isoform by its unique C-terminal E-peptide extension, which confers mechano-sensitive expression and distinct cell-signaling properties. MGF is extensively studied in preclinical muscle biology and is widely sold as a research-grade peptide. There are, as of 2026, no published human dose-finding or efficacy trials for exogenous MGF administration — a fact that is often obscured in vendor marketing materials.

What is MGF?

The IGF-1 gene (chromosome 12q23.2) undergoes complex alternative splicing to generate multiple mRNA isoforms. All isoforms share the same signal peptide, B, C, A, and D domains (the mature IGF-1 sequence); they differ in their 5' leader exons and in their C-terminal E-peptide extension. In humans, the predominant isoforms are IGF-1Ea (the systemic, liver-derived form, E-peptide from exon 6) and IGF-1Ec (MGF, E-peptide from exon 5, with a reading-frame shift). The IGF-1Ec designation reflects the Ec exon in humans; the rodent equivalent is termed IGF-1Eb. This species-specific nomenclature difference has been a source of confusion in the literature and in vendor descriptions of research peptides.

The Goldspink laboratory at UCL first identified the expression of an IGF-1 mRNA splice variant in response to mechanical stress in skeletal muscle in 1996. Goldspink and colleagues demonstrated that this splice variant — MGF — was preferentially expressed in damaged and mechanically loaded muscle relative to systemic IGF-1Ea, and that its expression was blunted in aged muscle, proposing a role in the decline of regenerative capacity with aging. Research in the Goldspink and related laboratories has produced substantial preclinical literature on MGF's role in satellite cell (muscle stem cell) activation, myoblast proliferation, and muscle hypertrophy in response to resistance exercise and injury.

The research-grade MGF peptide sold commercially typically refers to a synthetic 24-amino acid peptide representing the E-peptide of IGF-1Ec (the unique C-terminal domain of MGF), rather than the full-length MGF protein including the IGF-1 core. This distinction is important: the E-peptide alone has been proposed to have MGF-specific biological activity independent of IGF-1 receptor binding, but the evidence base for the isolated E-peptide is more limited than for the full splice variant protein. PEGylated MGF (PEG-MGF) is a modified form with extended half-life that has been studied in some preclinical contexts.

Mechanism of action

The IGF-1 core domain of MGF binds the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase, with affinity similar to other IGF-1 isoforms. IGF-1R activation triggers the PI3K/Akt/mTOR pathway (promoting protein synthesis, cell survival, and anabolic signaling) and the RAS/MAPK/ERK pathway (promoting cell proliferation). These mechanisms are shared with systemic IGF-1Ea. The unique biological interest in MGF lies in its distinct E-peptide domain.

The MGF E-peptide has been proposed to activate muscle satellite cells — resident muscle stem cells — through a receptor distinct from IGF-1R, promoting their proliferation without driving premature differentiation. This activity has been described as expanding the satellite cell pool available to repair damaged muscle fibers, in contrast to IGF-1's more direct differentiation-promoting effects. The E-peptide mechanism was characterized in a series of preclinical studies from the Goldspink laboratory and collaborators, though the putative receptor for the MGF E-peptide has not been definitively identified. A Frontiers in Endocrinology review (2012) critically evaluated the evidence for MGF as a distinct biological entity versus simply a precursor to mature IGF-1, noting methodological limitations in some foundational studies and the need for independent replication.

In addition to skeletal muscle, MGF has been studied in neurological contexts: a Molecular Brain study (2017, PMID 28683812) reported that systemic MGF promoted neurogenesis in the aging mouse brain hippocampus, and MGF has been investigated in an ALS mouse model (SOD1G93A mice), where peripheral administration reportedly improved motor neuron survival and muscle function (PMID 19038252). These findings extend the research interest in MGF beyond muscle biology but remain at the preclinical stage.

What the research shows — and what it doesn't

The published MGF literature is predominantly preclinical — rodent and cell-based studies. Key findings include: (1) MGF mRNA expression in skeletal muscle is upregulated by mechanical loading, resistance exercise, and eccentric muscle damage in both rodents and humans; (2) in vitro, the synthetic MGF E-peptide stimulates myoblast proliferation; (3) in rodent muscle injury models, local MGF injection or electroporation of MGF expression constructs has been reported to accelerate regeneration and increase muscle cross-sectional area; (4) in aging rodents, MGF expression is blunted compared to young animals, correlating with reduced regenerative capacity; (5) systemic administration of MGF protein or PEG-MGF in mice has been reported to produce some muscle anabolic effects.

Critical limitations of the MGF evidence base must be stated clearly. First, the preclinical literature is concentrated in a relatively small number of research groups, with limited independent replication of key claims. The Frontiers in Endocrinology 2012 review ('Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?') systematically examined the field and raised concerns about methodological heterogeneity, outcome measure variability, and the gap between gene-expression studies and protein-level effects. Second, no published human clinical trials have administered exogenous MGF peptide at any dose. There are no phase 1 safety studies, no dose-escalation studies, and no pharmacokinetic studies of exogenously administered MGF peptide in humans. Third, the commercial MGF E-peptide used in most research and sold to consumers is a 24-amino acid synthetic fragment, and its relationship to the endogenous full-length MGF splice variant protein is not fully established at the pharmacological level.

MGF is listed by the World Anti-Doping Agency (WADA) as a prohibited substance in the category of peptide hormones, growth factors, related substances, and mimetics. The anti-doping classification reflects WADA's precautionary approach to IGF-1-pathway substances with anabolic potential, not a determination that exogenous MGF has been demonstrated to enhance performance in humans. The presence of MGF on the WADA prohibited list has, paradoxically, increased its visibility in performance enhancement markets despite the absence of human clinical data.

Pharmacokinetics

The pharmacokinetics of exogenous MGF peptide in humans are entirely unknown — no human PK studies have been published. In preclinical research, the synthetic MGF E-peptide (24 amino acids) has a very short half-life in plasma due to proteolytic degradation, estimated at minutes in rodent studies. PEGylation (attachment of polyethylene glycol chains) has been used to extend half-life in experimental settings. The full-length MGF protein includes the IGF-1 core domain, which in its mature form is stabilized by IGF binding proteins (IGFBPs) in circulation; the E-peptide is cleaved during processing and may not circulate as a free peptide at meaningful concentrations. These processing dynamics complicate the interpretation of exogenous E-peptide administration.

Reported research dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

There are no published human dose-finding studies for exogenous MGF peptide. Preclinical research has used intramuscular or local injection of MGF E-peptide in rodents at doses ranging from micrograms to milligrams per kilogram in various models; these rodent doses have no validated relationship to human pharmacology. Any dosing information circulating in bodybuilding or research-peptide communities is entirely extrapolated from animal studies or from anecdotal reports, with no pharmacokinetic or safety basis in human clinical data. This represents a fundamentally different evidence landscape from peptides like semaglutide or even research peptides with completed phase 1 safety studies.

MGF is available from many research peptide vendors. Its commercial availability and WADA listing should not be mistaken for evidence of established human pharmacology. The compound has genuine scientific interest as a research tool in cell biology and animal models; its translation to human applications remains entirely uncharacterized.

Storage and handling

Research-grade MGF E-peptide is supplied lyophilized and should be stored at −20 °C, protected from moisture and light. The synthetic E-peptide (24 amino acids) lacks the disulfide bond present in some related peptides but is susceptible to proteolytic degradation by serum and tissue peptidases. Reconstitution in sterile PBS or aqueous buffer at neutral pH is typical for cell-based assay work. Aliquoted solutions should be stored at −80 °C for long-term use and at 2–8 °C for short-term use. Repeated freeze-thaw cycles should be avoided. PEG-MGF formulations, which have modified stability profiles, require vendor-specific storage guidance.

What MGF is NOT

MGF is not IGF-1 (insulin-like growth factor 1 LR3 or standard). IGF-1 LR3 is a long-acting recombinant analog of mature IGF-1 with an N-terminal extension that reduces IGFBP binding; MGF is a splice variant whose distinctiveness lies in its E-peptide, not modifications to the IGF-1 core. They share the IGF-1 receptor but have different tissue expression patterns, different processing pathways, and different proposed mechanisms for the E-peptide component. MGF is not HGH (growth hormone); GH stimulates IGF-1 production in the liver, but MGF is a locally produced splice variant whose expression is triggered by mechanical loading rather than circulating GH. MGF is not a GH secretagogue. MGF is not PEG-MGF: PEGylated MGF is a chemically modified derivative designed to extend the in vivo half-life of the E-peptide; PEG-MGF is a distinct research compound. MGF is also not GHRP-2, GHRP-6, ipamorelin, or any other GH-releasing peptide — these operate through entirely different receptor systems (GHSR / ghrelin receptor) and have no overlap with IGF-1 splice variant biology.

References

Primary sources include: the foundational Goldspink laboratory publications on MGF identification and expression; Yang et al.'s PLoS ONE study (PMC3795771) characterizing IGF-1Ec/MGF in the growth plate; Bates and Bhatt's 2012 Frontiers in Endocrinology critical review of MGF evidence ('an important cog or a loose screw?'); Ziegler et al.'s preclinical ALS work (PMID 19038252); Kazakos et al.'s neurogenesis study (PMID 28683812); and the anti-doping mass spectrometry characterization study (ScienceDirect, 2014). WADA prohibited list (current year) documents MGF's classification.